Humanetics expands lengthy COVID drug trial to more sites

Humanetics Corporation has expanded its clinical trial of a new oral drug, BIO 300, for long-haul Covid-19 (long Covid) to include two additional US study sites.

Montefiore Medical Center in the Bronx, New York, and the University of Texas Health Sciences Center in Houston, USA are the newer sites currently recruiting subjects.

These centers are in addition to the current clinical sites of NYU Langone and the Houston Methodist Research Institute.

The trial will analyze the ability of BIO 300 to attenuate long-term lung damage in subjects who have survived Covid-19.

Funded by the National Institutes of Health unit National Institute of Allergy and Infectious Diseases (NIAID), the trial will compare the lung function, exercise capacity and quality of life of trial subjects who will receive either BIO 300 or a placebo.

BIO 300 can be self-administered daily by patients for 12 weeks after discharge from hospital.

Humanetics Research Vice President Michael Kaytor said: “We do not fully understand the long-term effects of Covid-19 and are concerned that discharged patients continue to suffer from respiratory complications.

“Until now most of the attention has been on treating the acute phase of Covid-19 and now the focus is on the long-term effects of the initial infection.”

BIO 300 is developed as a medical countermeasure to protect the body from the harmful effects of ionizing radiation.

A US Department of Defense scientist discovered it while working on radiation protective therapies for the military.

Humanetics has further expanded the drug’s applications in cancer radiation therapy and concluded a trial in lung cancer patients who develop radiation therapy-related lung damage.

Normal lung damage caused by radiation in cancer patients is identical to lung damage caused by the SARS-CoV-2 virus.

The company claimed BIO 300 relieved radiation-induced lung inflammation and lung fibrosis and believes the same can be shown in patients with Covid-19.

In July 2020, the company secured funding from NIAID to evaluate BIO 300 in a trial for Covid-19.

Related companies